Cortexyme (CRTX) Stock Chart & Stock Price History $1.63 +0.02 (+1.24%) As of 08/22/2025 Add Compare Share Share Chart Stock AnalysisChartCompetitorsHeadlinesTrendsBuy This Stock Cortexyme Stock Price Performance The Cortexyme (CRTX) stock chart highlights key performance trends across multiple timeframes. Over the last 12 months, the stock's price has increased 154.29%, with a year-to-date return of -11.89%. In the past month, the stock has decreased 12.37%, reflecting recent market activity. As of the latest close, Cortexyme traded at $1.61 with a market cap of $48.54 million and volume of 61,949 shares. Five years ago, the stock traded at $42.11, representing a 96.13% decrease over that period. At the time, it had a market cap of $1.24 billion and a volume of 38,018 shares. Receive CRTX Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Cortexyme and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance-2.40%1 Month Performance-12.37%3 Month Performance+49.54%Year-To-Date Performance-11.89%1 Year Performance+154.29%5 Year Performance-96.13% CRTX Stock Chart for Sunday, August, 24, 2025 CRTX Chart by TradingView Cortexyme Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization08/22/2025$1.63$1.61-1.23%$1.66$1.6061,949 shs$48.54 million08/21/2025$1.61$1.63+1.24%$1.66$1.5974,395 shs$49.15 million08/20/2025$1.67$1.61-3.59%$1.70$1.60165,300 shs$48.54 million08/19/2025$1.69$1.67-1.18%$1.71$1.6681,632 shs$50.35 million08/18/2025$1.69$1.69$1.76$1.63166,060 shs$50.96 million08/15/2025$1.72$1.68-2.33%$1.78$1.66128,177 shs$50.65 million08/14/2025$1.83$1.72-6.01%$1.85$1.72256,720 shs$51.86 million08/13/2025$1.60$1.83+14.38%$1.93$1.56757,533 shs$55.18 million08/12/2025$1.65$1.60-3.03%$1.67$1.53236,137 shs$48.24 million08/11/2025$1.65$1.65$1.69$1.59188,611 shs$49.75 million Get the Latest News and Ratings for CRTX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Cortexyme and its competitors with MarketBeat's FREE daily newsletter. 08/08/2025$1.66$1.67+0.60%$1.70$1.55274,744 shs$50.35 million08/07/2025$1.69$1.66-1.78%$1.72$1.60336,562 shs$50.05 million08/06/2025$1.68$1.69+0.60%$1.75$1.65419,779 shs$50.96 million08/05/2025$1.68$1.68$1.70$1.6361,124 shs$50.65 million08/04/2025$1.68$1.68$1.70$1.6361,124 shs$50.65 million08/01/2025$1.65$1.69+2.42%$1.71$1.62143,878 shs$50.96 million07/31/2025$1.85$1.65-10.81%$1.75$1.64131,075 shs$49.75 million07/30/2025$1.85$1.85$1.88$1.80108,120 shs$55.78 million07/29/2025$1.85$1.85$1.88$1.80108,120 shs$55.78 million07/28/2025$1.85$1.85$1.88$1.80108,120 shs$55.78 million07/25/2025$1.86$1.86$1.88$1.75197,860 shs$56.08 million07/24/2025$1.90$1.86-2.11%$1.86$1.7773,708 shs$56.08 million07/23/2025$1.90$1.90$1.97$1.83241,726 shs$57.29 million Related Companies Omnicell Stock Price Chart HealthStream Stock Price Chart Veradigm Stock Price Chart Protalix BioTherapeutics Stock Price Chart Inhibikase Therapeutics Stock Price Chart ZIVO Bioscience Stock Price Chart Invizyne Technologies Stock Price Chart CEL-SCI Stock Price Chart JATT Acquisition Stock Price Chart Finch Therapeutics Group Stock Price Chart Receive CRTX Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Cortexyme and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:CRTX) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump’s “new dollar” could shock Americans"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.On a quiet Friday afternoon, one trader spotted an overlooked stock. He bought shares. He shut down his ...Timothy Sykes | SponsoredTrump’s SHOCKING Plan to Create MASSIVE Wealth for AmericansJames Altucher says Donald Trump just made a move so surprising, it could go down as the most lucrative presid...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cortexyme, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cortexyme With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access